Diabetes

Type 2 diabetes is an emerging epidemic driven by the escalating prevalence of obesity and by an ageing population. Diagnosis rates will continue to increase as improved awareness raises the public profile of the disease. Despite several established classes of oral anti-diabetic agents an unmet need for a safe, efficacious agent which can halt or reverse long-term disease progression remains.

Type 2 diabetes is an emerging epidemic with an estimated 55 million people affected by the condition in the seven major markets. Despite the raise profile of the disease physician research reveals that only approximately 50% of patients are diagnosed and of those around 80% receive treatment.

Novel classes of incretin mimetics, GLP-1 agonist and DDP-IV inhibitors, have the potential to improve time to secondary failure and are likely to be adopted by international guidelines in the near future. Despite the launch of these new products significant unmet needs remain in drug efficacy, safety and disease progression.

Long-term safety data is expected to become increasingly important following safety issues raised by recent meta-analyses of rosiglitazone over ischemic events. This will raise the safety bar for new products and is likely to lead to new classes requiring a long safety record before they are recommended as 1st- or 2nd- line therapies.

Read more...

• Type 1 Diabetes (28/06/2010)
• International Diabetes Summit (24/05/2010)
• International Diabetes Summit (24/05/2010)

• ACS in Europe (15/05/2008)
• Urinary Incontinence (15/05/2008)
• Autoimmune Overview (15/05/2008)
• Benchmarking key countries (15/05/2008)
• Reaching Patients Through Digital Media (15/05/2008)
• CNS Market Outlook (15/05/2008)
• Growth Opportunities in Generics (15/05/2008)
• Cardiovascular Market Outlook (15/05/2008)
• Innovations in Cancer (15/05/2008)

---